In the current study, we have presented evidence showing the effective inhibition of STAT3 activation by the small molecule inhibitor, Stattic, which resulted in decreased STAT3-mediated cyclin D1 expression and subsequent antitumor effects in NPC cells. The gene discussed is STAT3; the disease is nasopharyngeal carcinoma.